O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.48 CNY -6.16% Market Closed
Market Cap: 3.5B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Current Portion of Long-Term Debt
ÂĄ18.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Current Portion of Long-Term Debt
ÂĄ263.9m
CAGR 3-Years
17%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Current Portion of Long-Term Debt
ÂĄ449.4m
CAGR 3-Years
64%
CAGR 5-Years
16%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Current Portion of Long-Term Debt
ÂĄ1.1B
CAGR 3-Years
101%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Current Portion of Long-Term Debt
ÂĄ510.8m
CAGR 3-Years
23%
CAGR 5-Years
71%
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Current Portion of Long-Term Debt
ÂĄ1.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.5B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.5 CNY
Overvaluation 18%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
18.3m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Current Portion of Long-Term Debt amounts to 18.3m CNY.

What is Obio Technology Shanghai Corp Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
38%

Over the last year, the Current Portion of Long-Term Debt growth was 38%.

Back to Top